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One-fourth of all deaths in industrialized countries result from coronary heart disease. A century of
research has revealed the essential causative agent: cholesterol-carrying low-density lipoprotein
(LDL). LDL is controlled by specific receptors (LDLRs) in liver that remove it from blood. Mutations
that eliminate LDLRs raise LDL and cause heart attacks in childhood, whereas mutations that raise
LDLRs reduce LDL and diminish heart attacks. If we are to eliminate coronary disease, lowering LDL
should be the primary goal. Effective means to achieve this goal are currently available. The key
questions are: who to treat, when to treat, and how long to treat.Introduction
Among adults in industrialized countries, one-fourth of all deaths
result from arterial blockage caused by atherosclerotic plaques
(Heron, 2013). Most of these deaths are attributable to occlusion
of the coronary arteries, which produces heart attacks. Against
this background, it is quite surprising that heart attacks were
recognized as clinical entities a mere 100 years ago. Within 50
years, the disease had increased to epidemic proportions.
Only in recent years has the incidence of heart attacks in the
United States begun to decline (Levy, 2012).
The multifaceted path by which cholesterol became linked to
coronary heart disease is one of the great biomedical stories of
the 20th century. Table 1 shows major events in the century of
cholesterol and coronaries. It summarizes the scientific evidence
that converged from multiple disciplines to implicate cholesterol-
carrying low-density lipoprotein (LDL) as the instigator of athero-
sclerotic plaques and high dietary fat as the major cause of
pathologic LDL levels. We have divided the discoveries into two
sequential eras—first, the era of cholesterol and then the era
of LDL.
This Review focuses on selected discoveries that we consider
to be milestones in the century of cholesterol and coronaries. To
cover 100 years of a robust field in a 6,000-word essay, we were
forced to limit the literature that could be cited. We recognize
the important contributions of many uncited scientists whose
work deepened our understanding of cholesterol, LDL, and
coronary atherosclerosis. The reader should be aware that our
discussion of the SREBP pathway draws conclusions about
human liver physiology that represent extrapolations from ex-
periments in rats, mice, hamsters, and dogs. Inasmuch as mea-
surements of similar depth cannot be made on the livers of
human subjects, we believe that these extrapolations are justi-
fied by their explanatory potential for clinical and epidemiologic
observations.
Cholesterol-Rich Plaques in Humans and Rabbits
Atherosclerotic plaques on the surface of the aorta were
described by German pathologists in the 19th century (Leibo-witz, 1970). The word atherosclerosis is derived from the Greek
word atheros, which means gruel. It describes the cheesy sub-
stance that exudes from the plaques on sectioning. The first
hint that the cheesy substance was cholesterol came in 1910
when the German chemist Adolf Windaus found that plaques
from human aortas contained 25-fold more cholesterol than
normal aortas. Shortly thereafter, in 1913, Nikolaj Anitschkow,
a Russian pathologist, fed pure cholesterol to rabbits and pro-
duced profound atherosclerosis, thereby raising the possibility
that dietary cholesterol is the source of the gruel (Anitschkow
and Chalatow, 1913; Steinberg, 2005).
Heart Attacks Diagnosed in Living Patients
Although pathologists recognized that coronary arteries could
be occluded by atherosclerotic plaques, this was considered
to be a universally fatal event. Transient episodes of non-fatal
chest pain were attributed to indigestion or other non-cardiac
causes. This dogma was overturned in 1919, when the American
clinician JamesHerrick used the recently invented electrocardio-
graph machine to demonstrate changes in the electrical pattern
of the heart in patients who were experiencing severe non-fatal
chest pain (Herrick, 1919, 1944). By providing a method for the
firm diagnosis of heart attacks, the electrocardiogram ushered
in the modern era of cardiology.
Familial Hypercholesterolemia Described
The connection between plasma cholesterol and heart attacks
was put on firm genetic footing in 1938, when aNorwegian physi-
cian, Carl Mu¨ller, described families in which high plasma
cholesterol levels were transmitted as an autosomal dominant
trait (Mu¨ller, 1938). The disease was named familial hypercholes-
terolemia (FH), and it was soon recognized that the elevated
cholesterol levels were associated with a 20-fold increase in
the incidence of heart attacks in middle age.
First Description of Cholesterol Feedback
In 1933, Rudolph Schoenheimer, then working in Germany,
placed mice in sealed bottles, fed them a cholesterol-free diet,Cell 161, March 26, 2015 ª2015 Elsevier Inc. 161
Table 1. A Century of Cholesterol and Coronaries
First Half—The Era of Cholesterol
1910 Human atherosclerotic plaques contain cholesterol
1913 High cholesterol diet causes atherosclerosis in rabbits
1919 Heart attacks recognized in humans
1933 Feedback inhibition of cholesterol synthesis demonstrated
1938 Familial hypercholesterolemia described
1950 Cholesterol biosynthetic pathway elucidated
1951 High-fat diets raise plasma cholesterol in humans
1953 Risk factor concept advanced
Second Half—The Era of LDL
1955 LDL identified as risk factor for CHD
1973 LDL receptor discovered
1976 HMG CoA reductase inhibitors (statins) discovered
1981 Statins increase LDL receptors in vivo
1987 First statin (Mevacor) approved for human use
1994 Statins decrease heart attacks and prolong life
1997 SREBP pathway elucidated
2006 PCSK9: Destroyer of LDL receptorsand found that the cholesterol content of the bottles increased.
When the diet contained cholesterol, there was no longer a
contribution from the mice. This landmark study demonstrated
not only that animals can synthesize cholesterol, but also that
synthesis is inhibited when cholesterol is present in the diet
(Schoenheimer and Breusch, 1933). This was the first demon-
stration of the fundamental principle of end-product feedback
inhibition of a biosynthetic pathway, pre-figuring the classic
work of Jacob and Monod (1961), Pardee and Reddy (2003),
and Umbarger (1992). Schoenheimer’s discovery also laid the
groundwork for the discovery of the LDL receptor in the 1970s
(Goldstein and Brown, 2009) and the Scap/SREBP pathway in
the 1990s (Brown and Goldstein, 2009).
Cholesterol Biosynthetic Pathway Elucidated
In the 1950s, a small group of talented biochemists worked out
the complex pathway by which the 27-carbon, 4-ring cholesterol
molecule is synthesized through repeated polymerizations from
acetate, a simple 2-carbon building block attached to CoA. Most
prominent in this endeavor were Konrad Bloch and Feodor Ly-
nen, who shared the 1964 Nobel Prize in Physiology or Medicine
for their discoveries (Bloch, 1965; Zetterstro¨m, 2009). Of partic-
ular importance was the identification by Bucher and Lynen of
the 6-carbon compound 3-hydroxy-3-methylglutarate attached
to CoA (HMG CoA) as the first intermediate committed solely
to synthesis of cholesterol and other isoprenoids (Bucher et al.,
1960). This finding focused attention on HMG CoA reductase
as the rate-controlling enzyme in the cholesterol biosynthetic
pathway.
Risk Factor Concept Advanced
In 1951, Paul DudleyWhite and his colleague,MenardM.Gertler,
cardiologists at the Massachusetts General Hospital in Boston,
made careful observations on 100 people under age 40 who
had suffered heart attacks. They identified a series of risk factors
that predisposed to the disease (Gertler andWhite, 1954). These162 Cell 161, March 26, 2015 ª2015 Elsevier Inc.consisted of male sex, high blood cholesterol, elevated blood
pressure, cigarette smoking, positive family history, and ameso-
morphic body build. All of these are recognized as risk factors
today.
Seven-Country Study Invokes Dietary Fat
In 1953, the American physiologist Ancel Keys launched a land-
mark international epidemiological study of heart attacks. Keys
(1980) chose to study 16 cohorts of healthy men from specific
populations in seven different countries. The cohorts were cho-
sen mainly because their diets contained very different amounts
of total and saturated fat—ranging fromminimal fat in a cohort of
Japanese fishermen who thrived on vegetables, rice, and fish to
enormous amounts of fat in East Finnish foresters who habitually
spread butter on their cheese. For each of the 16 cohorts, Keys
ascertained 511 to 2,517 healthy men between the ages of 40
and 59 and followed them for 10 years, recording fatal and
non-fatal heart attacks (Keys, 1980). He found that serum
cholesterol rose in proportion to the total fat intake (r = 0.67)
and even more strikingly in proportion to the intake of saturated
fatty acids (r = 0.87). Fatal coronary events rose in proportion to
the serum cholesterol level (r = 0.80). At the two extremes, serum
cholesterol varied from a mean of 165 mg/dl in the Japanese
fishermen to 270 mg/dl in the East Finnish foresters. This differ-
ence was accompanied by a 13-fold higher incidence of coro-
nary events in the East Finnish. The other 14 cohorts lay more
or less on a line relating dietary saturated fat intake and serum
cholesterol. Although certain deviations from this line have
been proposed to contradict Keys’ conclusion, it is likely that
the deviations reflect local environmental or genetic factors
that modify the relation between fat intake, serum cholesterol,
and heart attacks in specific populations. However, they do
not negate Keys’ general conclusion that high fat intake leads
to high cholesterol and to heart attacks.
Keys’ observation that low dietary fat produces low blood
cholesterol and low heart attackswas supported by comparative
studies of Japanese men living in Japan, Hawaii, and California
(Keys et al., 1958). As the Japanese moved westward, their fat
intake increased, their plasma cholesterol rose, and the number
of heart attacks increased. Keys’ studies were performed before
plasma lipoproteins could be readily fractionated, and we
therefore consider them to conclude the first era in the story of
coronaries—the era of cholesterol.
LDL Identified as Major Risk Factor
The era of LDL began in 1955, when John Gofman, a physician/
physicist at the University of California, Berkeley, used the newly
invented analytical ultracentrifuge to separate the cholesterol-
carrying lipoproteins of plasma according to their density
(Gofman et al., 1954a). Two major fractions were identified:
low-density lipoproteins (LDL) and high-density lipoproteins
(HDL). When he studied plasma from heart attack patients, Gof-
man found a major increase in the cholesterol-carrying LDL. He
also observed a reduced level of HDL (Gofman et al., 1954b).
Gofman’s pioneering discoveries have been replicated many
times. The correlation between high LDL levels, low HDL levels,
and heart attacks is one of themost profound epidemiologic cor-
relations in all of medicine.
Figure 1. LDL, A Cholesterol Carrier
LDL is a spherical particle with a diameter of
220 nm and a mass of 3,000 kDa. Each particle
contains 1,500 molecules of cholesteryl ester in
an oily core that is shielded from the aqueous
plasma by a hydrophilic coat composed of 800
molecules of phospholipid, 500 molecules
of unesterified cholesterol, and 1 molecule of a
500 kDa protein, apoB.Gofman’s finding of a positive correlation with LDL led to
intense interest in this pathologic lipoprotein (Fredrickson
et al., 1967). In contrast, his finding of a negative correlation
with HDL received little attention until it was rediscovered 20
years later by epidemiologists, most notably in the Framingham
study (Gordon et al., 1977). Despite the enormous amount of
data correlating low HDL levels with increased heart attacks,
the mechanistic role of HDL in the pathogenesis of coronary dis-
ease is poorly understood and remains controversial despite 40
years of study. In marked contrast, elevations of plasma LDL
have been shown to produce atherosclerosis in every mamma-
lian species ever studied.
Figure 1 shows the structure of LDL. Each LDL particle con-
tains 1,500 molecules of cholesteryl ester in a hydrophobic
core surrounded by a polar phospholipid coat and a single
large protein called apolipoprotein B (apoB). A prevalent theory
states that LDL initiates atherosclerotic plaques when it pene-
trates through dysfunctional endothelium into the walls of ar-
teries (Bonetti et al., 2003). LDL is retained there, likely by its
propensity to bind to glycosaminoglycans. The lipids of LDL
become oxidized, and some of the reaction products modify
lysine residues on apoB (Steinberg and Witztum, 2010). The
modified apoB is recognized by scavenger receptors on macro-
phages and internalized by endocytosis, converting the macro-
phages to cholesterol-laden foam cells (Brown and Goldstein,
1983; Greaves and Gordon, 2009). The foam cells secrete a va-
riety of cytokines, thereby initiating an inflammatory reaction
(Hansson and Jonasson, 2009; Libby et al., 2011). In response,
smooth muscle cells in the arterial intima proliferate and pro-
duce collagen. The plaque enlarges and eventually ruptures,
leading to the formation of a blood clot that occludes the
vessel.
All other things being equal, the higher the LDL the faster the
plaques evolve. However, all other things are not equal. At any
given level of LDL, plaque formation is accelerated by risk factors
that include smoking, high blood pressure, and diabetes. In addi-
tion, poorly understood genetic factors affect atherosclerosis,
possibly by changing the susceptibility of the endothelium to
become damaged. Unless the LDL level is extraordinarily high
or low, it is difficult to predict accurately whether any individual
will suffer a heart attack.Cell 16LDL Receptor Pathway Elucidated
In 1972, we entered the field when we
began to study the regulation of choles-
terol synthesis in cultured human fibro-
blasts (Goldstein and Brown, 2009). We
were stimulated by our encounter with
two young siblings (ages 6 and 8) whowere hospitalized at the National Institutes of Health because
of recurrent heart attacks, owing to plasma LDL levels that
were 8-fold above normal. The children had the severe homozy-
gous form of familial hypercholesterolemia (FH), the disease that
was described in 1938 in its common heterozygous form by
Mu¨ller in Norway (see above) and later in its rare homozygous
form by Khachadurian (1964) in Lebanon. In the homozygous
children, each LDL particle was structurally normal, but they
had 8-fold more particles per ml of plasma as compared with
normal children. Homozygous FH is a rare disorder with a fre-
quency of 1 in 1 million people (Goldstein et al., 2001).
Frustrated at being unable to reduce the LDL level in these un-
fortunate children, we resolved to elucidate the genetic defect.
In 1972, shortly after moving to the University of Texas South-
western Medical Center in Dallas, we obtained skin biopsies
from three FH homozygotes and controls. From the biopsies,
we grewmonolayers of fibroblasts. Like all human cells, cultured
fibroblasts require cholesterol to maintain the integrity of their
plasma membranes. We found that normal fibroblasts obtained
cholesterol from two sources (Figure 2A). They synthesized
it from acetyl CoA through the pathway described by Bloch,
Lynen, and others, including the rate-controlling step catalyzed
by HMG CoA reductase. In addition, normal fibroblasts some-
how took up cholesterol from the LDL in the serum of the culture
medium. In sharp contrast, cells from FH homozygotes could not
take up cholesterol from LDL. They survived in culture because
they activated the cholesterol synthesis pathway to compensate
for the lack of LDL-derived cholesterol (Figure 2B). Their HMG
CoA reductase activity was 100-fold above normal (Goldstein
and Brown, 1973).
Working intensely for several years, we found the mechanism
for LDL uptake. The key is a cell surface receptor that binds
apoB. With our colleague Richard Anderson, we showed that
LDL receptors cluster in coated pits, regions of the cell surface
that are adapted for rapid internalization by endocytosis (Ander-
son et al., 1977; Goldstein et al., 1979). The internalized LDL is
delivered to lysosomes where the cholesteryl esters are hydro-
lyzed, and the cholesterol is released for newmembrane synthe-
sis. We also found that the production of LDL receptors and the
enzymeHMGCoA reductase are subject to coordinate feedback
suppression, as indicated by the dashed arrows in Figure 2A.1, March 26, 2015 ª2015 Elsevier Inc. 163
Figure 2. Feedback Regulation of Choles-
terol Synthesis and LDL Receptors in
Cultured Cells from Normal Subjects and
Children with Homozygous FH
(A) Normal cells obtain cholesterol from two
sources: (1) endogenous synthesis and (2) recep-
tor-mediated uptake and lysosomal hydrolysis
of LDL.
(B) Lacking LDL receptors, FH cells maintain
normal levels of cholesterol by increasing syn-
thesis of cholesterol, leaving excess LDL in the
culture medium.When cell cholesterol levels are low, the cells produce abundant
LDL receptors and HMG CoA reductase. When cellular choles-
terol levels rise, the levels of these two proteins decrease. The
net result is to keep the level of cholesterol in cell membranes
constant (Brown and Goldstein, 1986).
Defective LDL Receptors Cause FH
We found that the defect in FH lies in the gene for the LDL recep-
tor (Brown and Goldstein, 1974). Depending on the site of the
mutation in the LDL receptor gene, some FH homozygotes are
unable to produce any functional receptors (Figure 2B), whereas
others produce receptors with 5%–25%of normal activity (Gold-
stein et al., 2001). FH heterozygotes produce half the normal
number of functional receptors. Their LDL levels are elevated
by 2-fold, and they have heart attacks in their fifth and sixth
decades. The heterozygous form of FH is relatively common
for a single-gene disease, occurring in at least 1 in 500 people
in all populations (Goldstein et al., 2001).
LDL is secreted from the liver as a larger particle called very
low-density lipoprotein (VLDL) that contains triglyceride as well
as cholesterol. The triglycerides are extracted in adipose tissue
and muscle, causing the particle to shrink and become LDL.
Most LDL is removed from the circulation by LDL receptors164 Cell 161, March 26, 2015 ª2015 Elsevier Inc.located in the liver. When LDL receptors
are deficient, LDL particles circulate for
a prolonged time and build up to high
levels in plasma, eventually depositing
in arteries and thereby creating athero-
sclerotic plaques (Brown and Goldstein,
1986).
Our laboratory purified the LDL recep-
tor from bovine adrenal glands, which
use the receptor to supply cholesterol
for synthesis of steroid hormones
(Schneider et al., 1982). We obtained a
partial amino sequence and used it to
clone the cDNA and the gene (Yamamoto
et al., 1984; Su¨dhof et al., 1985). Located
on the short arm of chromosome 19, the
18 exons of the LDL receptor gene
encode a mature protein of 839 amino
acids. The receptor spans the plasma
membrane with its NH2 terminus facing
the exterior. The external segment con-
tains seven cysteine-rich repeats thatconstitute the LDL-binding site. The cytoplasmic COOH-termi-
nal segment of 50 amino acids contains the sequence that
guides the receptor to coated pits (Chen et al., 1990). To date,
more than 1,200 different allelic mutations in the LDL receptor
gene have been described in different families with FH (Usifo
et al., 2012). Some mutations destroy all function, while others
allow some residual activity.
Statins Inhibit HMG CoA Reductase and Increase LDL
Receptors
A therapeutic milestone occurred in 1976, when Akira Endo at
the Sankyo Company in Tokyo identified the first inhibitor of
HMG CoA reductase, thereby inaugurating the class of choles-
terol-lowering drugs known as statins (Endo et al., 1976). Endo’s
statin, called compactin, was isolated from a penicillium mold.
Knowing about the feedback suppression of LDL receptors,
we reasoned that an HMG CoA reductase inhibitor would
deprive liver cells of endogenous synthesis as a source of
cholesterol. This deprivation would relieve the feedback repres-
sion of LDL receptors, and the resultant increase in LDL recep-
tors would lower plasma LDL (Brown et al., 1978). In 1981, we
tested this hypothesis by treating dogs with mevinolin, another
fungal HMG CoA reductase inhibitor and closely related to
Figure 3. The SREBP Pathway for Choles-
terol Homeostasis in Animal Cells
(A) Cholesterol deficiency. When the cholesterol
content of ERmembranes falls below 5mol% of its
total lipids, Scap binds COPII proteins, which
incorporate the Scap/SREBP complex into COPII-
coated vesicles that move to the Golgi. In the
Golgi, SREBPs are cleaved by two proteases, S1P
and S2P, allowing the active portion to enter the
nucleus, where it activates genes that increase
cholesterol synthesis and uptake.
(B) Cholesterol excess. When ER cholesterol rises
above 5 mol% of membrane lipids, cholesterol
binds to Scap, thereby causing Scap to bind to
Insig. This releases COPII proteins, abrogating
transport to the Golgi. The fall in nuclear SREBP
reduces transcription of genes for cholesterol
synthesis and uptake.compactin, which was discovered by Alfred W. Alberts and col-
leagues at Merck (Alberts et al., 1980). As predicted, mevinolin
increased LDL receptors in the dog liver, and this led to amarked
fall in plasma LDL (Kovanen et al., 1981). Subsequent studies
by others showed that mevinolin (soon known as lovastatin or
Mevacor) and other statins lowered plasma LDL in humans
with diet-induced hypercholesterolemia (Vega and Grundy,
1991) and also in FH heterozygotes whose single functional
LDL receptor gene is susceptible to activation by cholesterol
deprivation (Mabuchi et al., 1981). Consistent with the LDL re-
ceptor theory, those FH homozygotes who had no functional
receptors showed no cholesterol lowering when treated with
mevinolin (Uauy et al., 1988).
First Statin Approved for Lowering LDL
In 1987, Merck’s Mevacor became the first statin approved for
human use (Brody, 1987; Byrne, 1987). The FDA approved
Mevacor based on studies showing that it lowers plasma LDL
and is well tolerated. At the time of approval, there was no evi-
dence that a statin could reduce heart attacks. This evidence
came in 1994, when Merck’s 4S Study (Scandinavian Simva-
statin Survival Study Group, 1994) demonstrated that a sec-
ond-generation statin, simvastatin, not only reduced heart
attacks, but actually prolonged life in middle-aged people at
high risk of a coronary event.
SREBP Discovered
The statin studies showed that the feedback regulation of LDL
receptors is of clinical importance, yet nothing was known ofCell 16the molecular mechanism by which
cholesterol regulated the synthesis and
supply pathways. Essentially all cellular
cholesterol is contained in membranes.
The feedback system optimizes the level
of cholesterol in those membranes. The
puzzle is: How does a cell measure the
level of cholesterol in its membranes,
and how is this information transmitted
to the nucleus to regulate gene transcrip-
tion? The first clue came in 1993, when
we isolated the key regulator—a tran-scription factor called sterol regulatory element-binding pro-
tein-1 (SREBP-1) (Yokoyama et al., 1993).
We purified SREBP-1 from the nuclei of cultured cells that were
deprived of cholesterol so that they actively transcribed the LDL
receptor gene. Our isolation procedure was based on the ability
of theprotein tobind toaDNAsequence required for LDL receptor
transcription (Wang et al., 1993). The purifiedprotein hadamolec-
ular mass of 60 kDa; yet when we cloned its cDNA, we were
greeted with two surprises. First, the protein purified from nuclei
was only a fragment of the full-length SREBP-1, which had a pre-
dicted molecular mass of 125 kDa (Yokoyama et al., 1993). And
second, the newly synthesized protein was bound tomembranes
by virtue of two transmembrane helices (Wang et al., 1994; Hua
et al., 1995). We were confronted with a problem: how does a
membrane-bound transcription factor move to the nucleus?
SREBP Pathway Elucidated
Over the next few years, we solved the movement problem, and
the result is the SREBP pathway shown in Figures 3A and 3B
(Brown and Goldstein, 1997; Goldstein et al., 2006). SREBPs
are synthesized as integral membrane proteins of the endo-
plasmic reticulum (ER). The cytosolic NH2-terminal segment
(molecular mass, 60 kDa) contains the basic helix-loop-helix-
leucine zipper sequence by which the protein binds to DNA
and activates transcription. Next is a hairpin membrane-attach-
ment domain comprising two transmembrane helices separated
by a 50 amino acid loop that projects into the ER lumen. At the
COOH-terminal end is a 65 kDa regulatory domain that projects
into the cytosol.1, March 26, 2015 ª2015 Elsevier Inc. 165
Immediately after its translation on membrane-bound ribo-
somes, SREBP binds to Scap, a polytopic protein of the ER
membrane (Hua et al., 1996). Scap has eight transmembrane he-
lices and a COOH-terminal extension that projects into the
cytosol, where it binds to the COOH-terminal regulatory domain
of SREBP (Sakai et al., 1998a). The cytosolic loop between heli-
ces 6 and 7 of Scap contains a sequence of six amino acids that
binds to a complex of proteins called COPII (Sun et al., 2007),
which were known previously to cluster certain ER proteins
into COPII-coated vesicles that bud from ER membranes
(Antonny and Schekman, 2001). These vesicles transport the
Scap/SREBP complex to the Golgi apparatus.
In the Golgi, SREBP is processed sequentially by two prote-
ases. The first, called site-1 protease (S1P), is a membrane-
bound serine protease that clips the SREBP in the luminal loop
(Sakai et al., 1998b). Cleavage separates the SREBP into two
membrane-bound halves. The NH2-terminal segment remains
bound to themembrane, owing to its singlemembrane-spanning
helix. It is released from the membrane by site-2 protease (S2P),
a hydrophobic zinc metalloprotease with its active-site zinc
buried in the membrane (Rawson et al., 1997; Feng et al.,
2007). S2P cleaves the NH2-terminal half of SREBP within its
membrane-spanning helix, releasing the transcriptionally active
segment so that it can enter the nucleus to activate transcription
of the LDL receptor gene. Intramembrane zinc metalloproteases
related to S2P are found as far back as archaea. We coined the
term regulated intramembrane proteolysis (RIP) to designate the
process by which membrane-bound proteins are released
by cleavage within a transmembrane helix (Brown et al., 2000).
Multiple examples of this regulatory mechanism are now known
(Urban, 2013).
Scap: A Sterol Sensor
Its location in the ERmembrane allows Scap to sense the level of
cholesterol in the membrane (Radhakrishnan et al., 2004, 2008).
When ER cholesterol rises above a threshold of 5%of total lipids,
the cholesterol binds to luminal loop 1 of Scap (Motamed et al.,
2011). This binding triggers a conformational change in luminal
loop 6 (Brown et al., 2002) that occludes the binding site for
COPII proteins (Sun et al., 2007). In its new conformation, Scap
binds to Insig, another polytopic protein of ER membranes
(Yang et al., 2002). Insig locks Scap into a conformation that
cannot bind COPII proteins, trapping the Scap/SREBP complex
in the ER, preventing Golgi processing, and thereby decreasing
transcription of the LDL receptor gene. Transcription remains
low until ER cholesterol falls and cholesterol-free Scap/SREBP
complexes can again bind COPII proteins.
Although SREBP-1 was isolated by virtue of its ability to acti-
vate transcription of the LDL receptor gene, we soon found that
the protein activates the gene for HMGCoA reductase as well as
the genes for all of the enzymes in the cholesterol biosynthetic
pathway, thereby allowing cells to synthesize cholesterol in addi-
tion to taking it up from LDL (Shimano et al., 1996; Horton et al.,
2003). SREBP-1 has two isoforms, SREBP-1a and -1c, which are
derived from alternate promoters that give rise to different first
exons (Shimomura et al., 1997). SREBP-1a is highly expressed
in rapidly growing normal and cancer cells; it activates fatty
acid synthesis as well as cholesterol synthesis, thereby supply-166 Cell 161, March 26, 2015 ª2015 Elsevier Inc.ing the major lipid components of cell membranes. SREBP-1c
is expressed primarily in liver, where it activates fatty acid syn-
thesis in response to insulin (Shimomura et al., 1999), thereby
contributing to fatty liver in type 2 diabetes (Moon et al., 2012).
A third isoform, SREBP-2, is produced by a different gene. It is
a relatively specific activator of the genes encoding the LDL
receptor and cholesterol biosynthetic enzymes (Horton et al.,
2003). All three SREBPs require processing by the SREBP
pathway (Horton et al., 2002).
Regulation of LDL Receptors by Diet, Drugs, and Genes
Figure 4 shows a model to explain how the regulation of
SREBP-2 in the liver is responsible for the LDL elevation pro-
duced by high-cholesterol/high-fat diets and the LDL-lowering
produced by statins. The model is based on experiments in
hamsters and mice (Sheng et al., 1995; Horton et al., 2002).
When the diet is low in cholesterol, liver cholesterol levels are
low and SREBP-2 enters the nucleus, where it activates the
LDL receptor gene, the HMG CoA reductase gene, and other
genes required for cholesterol synthesis (Figure 4A). The LDL
receptors keep plasma LDL low. High cholesterol diets cause
cholesterol to accumulate in hepatic ER membranes, blocking
SREBP-2 processing, reducing LDL receptors, and raising
plasma LDL (Figure 4B). In humans, the diet-mediated receptor
reduction is not complete or everyone would look like FH homo-
zygotes. It is not even 50% as in FH heterozygotes. However, it
is sufficient to raise LDL from the low levels seen in Japanese
fishermen to the higher levels accepted as normal in the U.S.
and other industrialized countries. Statins have the opposite
effect. By blocking cholesterol synthesis, statins lower ER
cholesterol, activating SREBP-2, increasing LDL receptors,
and lowering plasma LDL (Figure 4C). Nuclear SREBP-2 also in-
creases HMG CoA reductase, but cholesterol synthesis does
not increase, owing to statin inhibition. Strongly in favor of the
receptor induction mechanism is the observation that statins
do not lower LDL significantly in those FH homozygotes who
have null mutations in both copies of the LDL receptor gene
(Uauy et al., 1988).
Figure 5 illustrates the effects of diet, drugs, and genes on
plasma LDL and the consequent effects on coronary disease.
The top panel (Figure 5A) is a graphic representation of plasma
cholesterol levels in the human species as extrapolated from
surveys of middle-aged people in major populations of the
world. We use total cholesterol values because there are
more measurements of total cholesterol than of LDL. However,
differences in total cholesterol closely reflect differences in LDL.
The distribution of total cholesterol levels is highly skewed. The
data predict that the median cholesterol level for the human
species is 170 mg/dl. This is attributable to the large number
of people in China and other Asian populations, where the his-
torical mean cholesterol level is about 150 mg/dl (Chen et al.,
1991; Junshi et al., 1990). In North America and Europe, the
mean value is 220 mg/dl. The incidence of heart attacks cor-
relates with these levels. Almost unheard of in China and Japan
before recent increases in their fat intake, heart attacks are
much more frequent in Europe and the U.S., especially when
plasma cholesterol exceeds 220 mg/dl (graduated red shading
in Figure 5A).
Figure 4. Hepatic Response to Diet and
Statins Mediated by the SREBP Pathway
(A) Low-cholesterol diet. Proteolytic cleavage of
SREBP is increased. The cleaved SREBP enters
the nucleus to activate genes controlling choles-
terol synthesis (including HMG CoA reductase)
and uptake (LDL receptor). nSREBP, nuclear
portion of cleaved SREBP.
(B) High-cholesterol diet. Proteolytic cleavage of
SREBPs is decreased, resulting in decreased nu-
clear SREBP and decreased activation of target
genes. The decrease in LDL receptors produces
an increase in plasma LDL.
(C) High-cholesterol diet plus statin therapy.
Statins inhibit HMG CoA reductase, causing a
transient decrease in ER cholesterol. In response,
SREBP cleavage is increased, and the resulting
nuclear SREBP activates the genes for HMG CoA
reductase and LDL receptor. The increased HMG
CoA reductase is inhibited by the statin, and the
increased LDL receptors lower plasma LDL.Statins Reduce Heart Attacks and Prolong Life
Figure 5B summarizes the results of four double-blind, placebo-
controlled trials in which middle-aged people at high risk for
heart attacks were treated for 5 years with a statin or placebo
(38,153 total subjects). The results are remarkably consistent.
In each case, lowering LDL reduced heart attacks with no evi-
dence for a lower threshold (Scandinavian Simvastatin SurvivalCell 16Study Group, 1994; Sacks et al., 1996;
LIPID, 1998; Heart Protection Study
Collaborative Group, 2002). In the largest
study, the Heart Protection Study (HPS),
20,536 subjects were treated with simva-
statin for 5 years. The study was large
enough to allow multiple subgroup ana-
lyses. These showed that the reduction
in relative risk was similar even when sub-
jects had risk factors, including diabetes,
hypertension, and smoking. A recent
meta-analysis of 22 statin trials involving
134,000 participants concluded that,
for each reduction of LDL cholesterol
of 1 mmol/l (40 mg/dl), cardiovascular
events are reduced by 20%, even in peo-
ple who were considered to be at low
risk (Mihaylova et al., 2012). Considered
together, these statin trial results strongly
support the dominant role of LDL in coro-
nary disease.
PCSK9: AProtein that Destroys LDL
Receptors and Raises LDL
The genetic connection between LDL and
heart attacks was established by muta-
tions in LDL receptors that raise LDL
and increase coronary events (Brown
and Goldstein, 1986). Recently, the other
side of the coin was exposed—namely,
mutations that increase LDL receptors,lower LDL, and reduce coronary events (Cohen et al., 2006; Abi-
fadel et al., 2014). Themutations occur in a gene that encodes an
enzyme called PCSK9, which stands for proprotein convertase
subtilisin/kexin type 9 (Horton et al., 2009). Secreted into plasma
by liver and other organs, PCSK9 binds to hepatic LDL receptors
and disrupts the recycling mechanism that returns the receptors
to the cell surface after internalization (Lagace et al., 2006; Zhang1, March 26, 2015 ª2015 Elsevier Inc. 167
Figure 5. Diagram Illustrating the Effects of Diet, Drugs, and Genes
on Plasma LDL and Coronary Disease
(A) Diet. Idealized depiction of the frequency distribution of plasma cholesterol
levels in the human species as extrapolated from surveys of middle-aged
people in major populations of the world. The higher the cholesterol level, the
higher the risk for coronary disease, as denoted by the graded red shading.
(B) Drugs. Frequency of coronary events plotted against plasma level of LDL
cholesterol in four double-blind, placebo-controlled trials in which middle-
aged people at risk for heart attacks were treated for 5 years with a statin or
placebo. The number of subjects in each study was as follows: 4S Study,
4,444; LIPID, 9,014; CARE, 4,159; and HPS, 20,536.
(C) Genes. Difference in risk for coronary disease in middle-aged people de-
pending on whether plasma LDL cholesterol level is reduced over a lifetime
(heterozygous loss of function of PCSK9) or for only 5 years (statin therapy).et al., 2007). As a result, the number of cell-surface LDL recep-
tors declines and LDL rises. Inasmuch as PCSK9 circulates in
the plasma of normal individuals, plasma LDL is never as low
as it would be if LDL receptors were functioning maximally.
The relation between PCSK9 and LDL receptors was discov-
ered by Abifadel et al. (2003) in studies of rare patients with
gain-of-function mutations that increase the activity of the
protein. Affected individuals have high LDL levels that are trans-168 Cell 161, March 26, 2015 ª2015 Elsevier Inc.mitted as an autosomal-dominant trait. The reverse phenome-
non was discovered by Cohen and Hobbs, who identified people
with common loss-of-function mutations in PCSK9 that lead to
low LDL levels and protect against heart attacks (Cohen et al.,
2006). Three percent of Caucasians are heterozygous for a
missense mutation (R46L) that partially inactivates PCSK9. On
average, these individuals have a 15% reduction in plasma
LDL when compared with age-matched controls. Remarkably,
they have a 46% reduction in early coronary events. Even
more striking, 2% of African-Americans are heterozygous for
one of two nonsense mutations (either Y142X or C679X) that
inactivate one copy of the PCSK9 gene. Their LDL levels are
reduced by 28%, and they have an 88% reduction in heart
attacks when studied at a mean age of 54 years (Cohen et al.,
2006).
Cohen and Hobbs’ finding of a 45% lowering of coronary
events in Caucasians with missense mutations in PCSK9 was
rapidly confirmed in two other studies (McPherson and Kavaslar,
2007; Kathiresan, 2008). The reduction in coronary disease in in-
dividuals with diminished PCSK9 occurs despite the presence of
other risk factors, including hypertension, diabetes, and smok-
ing. This finding correlates with the finding in the HPS study
that LDL lowering with a statin can reduce heart attacks even
when other risk factors are present (Heart Protection Study
Collaborative Group, 2002).
LDL Reduction: Better Sooner Than Later
The observations on subjects with PCSK9 mutations suggest
strongly that lifelong LDL reductions are much more effective
than late LDL reductions in preventing coronary events.
Figure 5C compares the reduction in coronary disease in
PCSK9 heterozygotes and the reduction observed in people in
5-year clinical trials whose LDL was lowered by a statin. When
statins lower LDL by 15%, they lower coronary events by 15%,
which is much less than the 45% reduction observed when
LDL is reduced to a similar degree by a PCSK9 mutation. Simi-
larly, when statins lower LDL by 30%, they lower coronary events
by 30%—far weaker than the nearly 90% event reduction
observed when LDL is lowered by 30% as a result of a PCSK9
mutation. Why is the protective effect of the PCSK9 mutations
somuch greater than can be achieved by statins? Themost likely
explanation lies in the duration of the LDL lowering (Brown and
Goldstein, 2006). People with PCSK9 mutations have low LDL
levels throughout life, and they may never have developed
atherosclerotic plaques. In the statin trials, patients were not
treated until they were at high risk of a coronary event, which
means that they already had established atherosclerosis. Once
the disease is established, patients may require much more
severe LDL lowering to prevent an event.
It is noteworthy that the 90% reduction in coronary events in
people with null mutations in PCSK9 is similar to the 90% reduc-
tion observed by Ancel Keys when he studied Japanese fisher-
men who had low LDL levels throughout life (Keys, 1980). The
advantage of lifelong low LDL is further illustrated by a recent
study of subjects who absorb reduced amounts of cholesterol
from the intestine as a result of loss-of-function mutations in
NPC1L1, the intestinal cholesterol transporter. Lifelong reduc-
tions of only 11% in LDL produced a 53% reduction in heart
attacks (The Myocardial Infarction Genetics Consortium Investi-
gators, 2014). Thus diet, genes, and drugs all yield the same
conclusion, namely, that LDL lowering can prevent heart attacks,
especially when the lowering is begun before atherosclerotic
plaques have developed.
Based on the high affinity of the LDL receptor for LDL, in 1977
we postulated that the human body is designed to maintain LDL
cholesterol levels in the range of 25 mg/dl (Goldstein and Brown,
1977, 1982). Indeed, plasma LDL cholesterol levels in adults from
most other animals so far studied, including primates, are lower
than 60 mg/dl (Mills and Taylaur, 1971; Chapman and Goldstein,
1976). In newborn humans, LDL cholesterol is less than 50mg/dl
(Kwiterovich et al., 1973). LDL levels above 100 mg/dl are
frequent only in humans or other animals that have consumed
the typical Western diet, which is high in fat and cholesterol.
The dramatic reductions in coronary events in people with
PCSK9mutations stimulated several pharmaceutical companies
to produce monoclonal antibodies that bind to PCSK9 and inac-
tivate it. Data from two early trials show that these antibodies can
reduce plasma LDL by asmuch as 40%when given alone and by
60% when added to a statin regimen (Stein et al., 2012; Raal
et al., 2012). Just like statins, anti-PCSK9 antibodies fail to
reduce LDL significantly in those FH homozygotes who lack all
LDL receptor activity (Stein et al., 2013), further supporting the
role of LDL receptors in lowering LDL. Studies are underway to
determine the long-term safety of anti-PCSK9 antibodies and
their efficacy in preventing heart attacks (Young and Fong,
2012; Vogel, 2012).
Accomplices of LDL
The data reviewed here focus on LDL as the sine qua non of
atherosclerosis. However, LDL does not act alone. Evidence
from genetically manipulatedmice indicates that the atherogenic
effect of LDL requires macrophages and inflammatory cytokines
(Glass and Witztum, 2001; Libby et al., 2011). In humans, at any
given level of LDL, the probability of a myocardial infarction is
increased by well-documented risk factors that include cigarette
smoking, hypertension, diabetes, and low HDL. Although these
contributory factors are important, they all require LDL to insti-
gate the lesion. The epidemiologic data in China and Japan, the
genetic data with PCSK9 and NPC1L1 deficiency, and the thera-
peutic data with statins demonstrate that myocardial infarctions
can be markedly diminished by LDL lowering even when macro-
phages, cytokines, and risk factors are present. Fortunately, we
now have the ability to lower LDL with diet and with drugs.
The Next Century
The past 100 years have witnessed the crest of the coronary
disease epidemic in Western countries and its beginning reces-
sion. Scientists have made dramatic advances in understanding
cholesterol, the lipoproteins that carry it in plasma, and the
manner inwhich genes and diets alter lipoprotein levels. The cen-
tury of cholesterol research produced four lines of evidence—
experimental, genetic, epidemiologic, and therapeutic—that
converge upon LDL as the primary cause of atherosclerosis.
Few, if any, chronic diseases have been subjected to such inten-
sive scrutiny, and rarely has the cause and the approach to pre-
vention been documented so convincingly.It does not seem an exaggeration to state that targeted appli-
cation of an LDL-lowering regimen may eventually curtail one of
themajor killers of the last century. The key questions for the 21st
century are who to target and when. Ideally, LDL-lowering ther-
apy should be initiated before atherosclerotic plaques develop
or at least before they develop their most threatening features.
Currently, we base our decisions for LDL lowering on factors
such as the absolute level of LDL, the presence of other risk fac-
tors, and a family history of early coronary disease. In the future,
we may be able to use genetic polymorphisms that render ar-
teries susceptible or resistant to LDL entry and susceptible or
resistant to the ensuing inflammation. Such genetic polymor-
phisms may increase our assessment of risk, but they are un-
likely to be absolute. Our decisions would be greatly helped if
someone develops a noninvasive method to detect the earliest
atherosclerotic plaques in the coronary arteries, to monitor their
growth, and to detect the earliest signs of the inflammation and
instability that lead to thrombosis. Given such a method for early
detection and given our powerful methods to lower LDL, we
should surely be able to end the epidemic of heart attacks that
killed so many over the last century.
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